Santen Pharmaceutical (OTCMKTS:SNPHY) Stock Price Down 4.7% – Here’s What Happened
by Renee Jackson · The Cerbat GemSanten Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) shares were down 4.7% on Monday . The company traded as low as $11.1083 and last traded at $11.1083. Approximately 1,570 shares changed hands during trading, a decline of 87% from the average daily volume of 12,405 shares. The stock had previously closed at $11.6540.
Analysts Set New Price Targets
Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a research report on Monday. One analyst has rated the stock with a Hold rating, According to MarketBeat, the stock currently has a consensus rating of “Hold”.
Read Our Latest Stock Analysis on Santen Pharmaceutical
Santen Pharmaceutical Stock Up 5.9%
The company has a 50-day simple moving average of $11.03 and a two-hundred day simple moving average of $10.66. The firm has a market cap of $3.78 billion and a PE ratio of 0.10.
Santen Pharmaceutical Company Profile
Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.
With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.